Page 8 - Interim Analysis News Today

Helix BioPharma Corp announced the appointment of Artur Gabor as the companys new permanent CEO, effective immediately. The clinical-stage...

Revive Therapeutics Ltd (CSE:RVV, OTCQB:RVVTF) announced the publication of a scientific article evaluating the impact of medication, including Bucillamine,...

Coronavirus Treatment and Cure news - updated 24/7/365. We link to the best sources from around the world. Get the latest news…

The board released its 2021 annual report on Thursday, highlighting its main accomplishments as it transitioned to a mostly new board.

Biophytis / Key word(s): MiscellaneousBiophytis provides updates on Sarconeos (BIO101) clinical development 07-Apr-2022 / 08:00 CET/CESTBiophytis provides updates on Sarconeos (BIO101)clinical development  Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia,...

Biophytis / Key word(s): Annual ResultsBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives 07-Apr-2022 / 08:00 CET/CESTBiophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives  Success of Nasdaq IPO in February 2021 €23.9M o...

DGAP-News: ABIVAX / Key word(s): Study results Abivax reports excellent one-year efficacy and safety data of ABX464 phase 2b maintena...

Interim Analysis in Phase 2 CANAL Trial Showed Primary Efficacy Endpoint of Cough Reduction in Idiopathic Pulmonary Fibrosis was Highly Statistica...

Enrollment of 644 Evaluable Patients Expected to Enable Second Interim Analysis in the Second Half of 2022 First Interim Analysis of 418 Evaluable Patients Remains on Track for the First Half of 2022 Data

Investegate announcements from NuCana plc, NuCana Announces Enrollment of Required Number of Patients to Conduct Second Interim Analysis in the Phase III Biliary Tract Cancer Study